"A recent study shows an abnormal diffuse inflammatory cytokine profile that persists in Long COVID patients for at least 8 months, not found in asymptomatic COVID-19 survivors.
Studies of Long COVID patients have shown persistent deregulation of a broad range of cytokines long after infection. Specifically, it is shown that IL-1β, IL-6 and TNF-α remain elevated in Long COVID - PASC. This is despite the fact that peripheral blood cytokines do not need to be elevated, since they function by acting locally rather than by flowing through the blood. Nevertheless, persistent immune activation has been suggested to be associated with ongoing symptoms following COVID-19."
https://www.frontiersin.org/articles/10.3389/fmed.2023.1011936/full#:~:text=A%20recent%20study%20shows%20an,of%20cytokines%20long%20after%20infection.
=> Remestemcel-L POSSIBLY helping with long-COVID too....
- Forums
- ASX - By Stock
- MSB
- RWE for 2nd MSB COVID-19 ARDS P3 Trial
RWE for 2nd MSB COVID-19 ARDS P3 Trial, page-904
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
99.0¢ |
Change
0.030(3.13%) |
Mkt cap ! $1.130B |
Open | High | Low | Value | Volume |
96.5¢ | $1.03 | 96.5¢ | $4.704M | 4.708M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 87395 | 98.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.00 | 274051 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 1.000 |
5 | 23430 | 0.990 |
4 | 52000 | 0.985 |
3 | 6800 | 0.980 |
2 | 12101 | 0.970 |
Price($) | Vol. | No. |
---|---|---|
0.945 | 15867 | 1 |
0.990 | 25 | 1 |
0.995 | 6 | 1 |
1.000 | 50677 | 3 |
1.005 | 57507 | 4 |
Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online